Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO) yesterday and set a price target of $62.00. The company’s shares closed last Wednesday at $40.33.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 7.8% and a 45.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $58.86 average price target, which is a 52.1% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $68.00 price target.
See today’s analyst top recommended stocks >>
Based on Albireo Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.91 million and GAAP net loss of $20.6 million. In comparison, last year the company earned revenue of $1.25 million and had a GAAP net loss of $16.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
